This update in the health sector highlights major developments including DiaSorin's significant profit growth, GSK's RSV ...

GSK has received Canadian approval for its respiratory syncytial virus vaccine in adults between 50 and 59, the company said ...

Preliminary data were announced from 2 clinical trials evaluating Arexvy in a broader population of adults at increased for RSV disease.

Quarterly sales of GSK's RSV vaccine dropped more than 70%, following narrower recommendations for who should get the shot.

The British pharma’s experience during the third quarter mirrored that of rival Pfizer, which also reported lower sales of ...

To hear GSK CEO Emma Walmsley tell it, the third quarter presented “some challenges” for the drugmaker. | To hear GSK CEO ...

GSK reports Q3 sales of $10.42 billion, missing estimates due to an 18% drop in vaccine revenue, while specialty medicines ...

GSK's shares are falling 4% in premarket trading Wednesday after the British pharma giant posted lower-than-estimated quarterly sales and lowered its projection for vaccine sales ...

Sales GSK Plc’s leading vaccines sank in the third quarter after the British drugmaker was hit by limited access to the shots ...

The drugmaker said sales of Arexvy fell sharply in the third quarter, but cancer and HIV treatments saw a stronger performance.

GSK on Wednesday said its vaccine sales would fall this year, after a weaker-than-expected performance for its respiratory ...

GSK remains on fairly stable financial footing, with a debt/EBITDA ratio of 2.1 at the end of 2023 and Haleon taking on close to GBP 10 billion of GSK's debt in the 2022 divestment. With the improving ...